IDEAYA Biosciences Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, has appointed Stu Dorman as Chief Commercial Officer.
 
Dorman has a track record of commercial success in numerous specialty disease areas with over 20 years of oncology and hematology experience.
 
Prior to joining IDEAYA, he was the Vice President and head of the U.S. Oncology Business Unit at Gilead Sciences, where he built a leading oncology commercial organization with over a billion in global annual sales and successfully launched Trodelvy in multiple indications.
 
Prior to that, Dorman held positions of increasing responsibility at Bristol Myers Squibb (BMS), where he built, led, and transformed global sales and marketing teams to deliver outstanding commercial execution, including multiple successful launches. He concluded his 14-year tenure at BMS as Vice President, Worldwide Oncology Commercialization in its diverse oncology portfolio.
 
He received his M.B.A. from Stanford Graduate School of Business and his A.B. in Economics with Honors from Harvard University.
 
“We are thrilled to welcome Stu as IDEAYA makes continued enrollment progress in the potential registrational trial for darovasertib in first-line HLA-A2(-) MUM, and the potential indication expansion opportunity in neoadjuvant UM. Stu has extensive commercial experience in global product commercialization, product launches, sales and market access. Most importantly, Stu’s proven track record in maximizing the commercial opportunity for several global blockbuster cancer treatments, such as Trodelvy and Opdivo, makes him an ideal fit to lead our commercial organization,” said Yujiro S. Hata, President and CEO of IDEAYA Biosciences.
 
“I am delighted to join IDEAYA to build an industry-leading commercial organization that is well-positioned to deliver potential first-in-class precision medicine oncology therapies that can improve the lives of cancer patients worldwide. I look forward to leveraging my extensive commercial oncology experience as darovasertib continues to make progress in the potential registrational trial in first-line HLA-A2(-) MUM and targeted Phase 3 start in neoadjuvant UM, and as the broader clinical pipeline advances, including IDE397 in MTAP-deletion non-small cell lung cancer and urothelial cancer,” Dorman remarked.